Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CPSC leadership

This article was originally published in The Tan Sheet

Executive Summary

Nomination of Harold Stratton to chair Consumer Product Safety Commission, take over as commissioner for remainder of term expiring Oct. 26, 2006, sent to the Senate March 13. Nomination will go before the Commerce Committee; no confirmation hearings have been scheduled. Bush Administration announced its choice in November, after Mary Sheila Gall's nomination was defeated by Senate Democrats (1"The Tan Sheet" Nov. 5, 2001, In Brief)...

You may also be interested in...


President Bush nominates Harold Stratton to chair Consumer Product Safety Commission. Albuquerque lawyer is "known consumer advocate" who served as New Mexico's AG (1987-1990) and in state's House of Representatives (1979-1986), White House says. Stratton is a partner with the law firm Stratton & Cavin. No Senate confirmation hearings have been scheduled. Bush Administration abandoned its push to appoint Mary Sheila Gall as commission chair after her nomination was defeated in committee by Senate Democrats (1"The Tan Sheet" Aug. 6, p. 6). Commissioner Thomas Moore named acting chairman after Ann Brown's previously announced resignation took effect Nov. 1...

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 


Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts